PDF(Pubmed)
Abstract：
Hypertension is a major controllable risk factor associated with cardiovascular disease (CVD) and overall mortality worldwide. Most people with hypertension must take medications that are effective in blood pressure management but cause many side effects. Thus, it is important to explore safer antihypertensive alternatives to regulate blood pressure. In this study, peanut protein concentrate (PPC) was hydrolyzed with 3-5% Alcalase for 3-10 h. The in vitro angiotensin-converting enzyme (ACE) and renin-inhibitory activities of the resulting peanut protein hydrolysate (PPH) samples and their fractions of different molecular weight ranges were determined as two measures of their antihypertensive potentials. The results show that the crude PPH produced at 4% Alcalase for 6 h of hydrolysis had the highest ACE-inhibitory activity with IC50 being 5.45 mg/mL. The PPH samples produced with 3-5% Alcalase hydrolysis for 6-8 h also displayed substantial renin-inhibitory activities, which is a great advantage over the animal protein-derived bioactive peptides or hydrolysate. Remarkably higher ACE- and renin-inhibitory activities were observed in fractions smaller than 5 kDa with IC50 being 0.85 and 1.78 mg/mL. Hence, the PPH and its small molecular fraction produced under proper Alcalase hydrolysis conditions have great potential to serve as a cost-effective anti-hypertensive ingredient for blood pressure management.
摘要：
高血压是全球范围内与心血管疾病（CVD）和总死亡率相关的主要可控危险因素。大多数高血压患者必须服用对血压管理有效但会引起许多副作用的药物。因此，重要的是探索更安全的抗高血压药物来调节血压。在这项研究中,花生蛋白浓缩物（PPC）用3-5％的Alcalase水解3-10h。测定了所得花生蛋白水解物（PPH）样品及其不同分子量范围的馏分的体外血管紧张素转换酶（ACE）和肾素抑制活性，作为其降压潜力的两种量度。结果表明，在4％Alcalase水解6h时产生的粗PPH具有最高的ACE抑制活性，IC50为5.45mg/mL。用3-5％Alcalase水解6-8小时产生的PPH样品也显示出实质性的肾素抑制活性，与动物蛋白来源的生物活性肽或水解产物相比，这是一个很大的优势。在小于5kDa的级分中观察到显著更高的ACE和肾素抑制活性,IC50为0.85和1.78mg/mL。因此，在适当的Alcalase水解条件下产生的PPH及其小分子组分具有很大的潜力,可作为一种经济有效的抗高血压成分用于血压管理.
